Mateon Therapeutics, Inc. (OTCMKTS:MATN – Get Free Report)’s stock price crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $0.05 and traded as high as $0.07. Mateon Therapeutics shares last traded at $0.07, with a volume of 1,217,287 shares changing hands.
Mateon Therapeutics Trading Up 14.9%
The business has a 50-day moving average price of $0.05 and a two-hundred day moving average price of $0.05.
Mateon Therapeutics Company Profile
Mateon Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-beta, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus.
Featured Articles
- Five stocks we like better than Mateon Therapeutics
- What is the Dow Jones Industrial Average (DJIA)?
- Tesla: 2 Reasons to Love Musk’s $1B Buy, 1 Reason to Be Bearish
- Investing In Preferred Stock vs. Common Stock
- Azure Leads While AI Excitement Fuels Microsoft Stock
- The Basics of Support and Resistance
- Darden Restaurants: A Textbook Buy-the-Dip Opportunity
Receive News & Ratings for Mateon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mateon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
